Back to Search Start Over

Comprehensive cancer-oriented biobanking resource of human samples for studies of post-zygotic genetic variation involved in cancer predisposition

Authors :
Kinga Drężek
Łukasz Bełch
Rafał Pęksa
Karol Sasim
Joanna Szpor
Marek Sierzega
Ewa Śrutek
Wojciech Zegarski
Edyta Rychlicka-Buniowska
Marcin Przewoźnik
Monika Horbacz
Łukasz Kaska
Arkadiusz Piotrowski
Dorian Wiśniewski
Krzysztof Okoń
Marek Zdrenka
Karol Tkaczyński
Michał Jankowski
Agnieszka Adamczyk
Dariusz Bała
Katarzyna Chojnowska
Krzysztof Kamecki
Wiktoria Stańkowska
Aleksandra Ambicka
Łukasz Szylberg
Diana Hodorowicz-Zaniewska
Janusz Jaszczyński
Magdalena Wójcik
Urszula Ławrynowicz
Mikolaj Przydacz
Jakub Szymanowski
Jarosław Kobiela
Hanna Davies
Izabela Ratnicka
Karol Wierzba
Janusz Ryś
Stanisław Hać
Jarosław Skokowski
Natalia Filipowicz
Jerzy Jankau
Agata Wojdak
Ulana Juhas
Andrzej Hellmann
Marta Drzewiecka
Wojciech Makarewicz
Piotr Remiszewski
Paweł Wroński
Karol Polom
Michał Bieńkowski
Katarzyna Duzowska
Jerzy Siekiera
Marcin Matuszewski
Jacek Kowalski
Jan P. Dumanski
Katarzyna Milian-Ciesielska
Maria Andreou
Olga Rostkowska
Tomasz Nowikiewicz
Agnieszka Harazin-Lechowska
Piotr Chlosta
Publication Year :
2021
Publisher :
Cold Spring Harbor Laboratory, 2021.

Abstract

The progress in translational cancer research relies on access to well-characterized samples from a representative number of patients and controls. The rationale behind our biobanking are explorations of post-zygotic pathogenic gene variants, especially in non-tumoral tissue, which might predispose to cancers. The targeted diagnoses are carcinomas of the breast (via mastectomy or breast conserving surgery), colon and rectum, prostate, and urinary bladder (via cystectomy or transurethral resection), exocrine pancreatic carcinoma as well as metastases of colorectal cancer to the liver. The choice was based on the high incidence of these cancers and/or frequent fatal outcome. We also collect age-matched normal controls. Our still ongoing collection originates from five clinical centers and after nearly 2-year cooperation reached 1711 patients and controls, yielding a total of 23226 independent samples, with an average of 74 donors and 1010 samples collected per month. The predominant diagnosis is breast carcinoma, with 933 donors, followed by colorectal carcinoma (383 donors), prostate carcinoma (221 donors), bladder carcinoma (81 donors), exocrine pancreatic carcinoma (15 donors) and metachronous colorectal cancer metastases to liver (14 donors). Forty percent of the total sample count originates from macroscopically healthy cancer-neighboring tissue, while contribution from tumors is 12%, which adds to the uniqueness of our collection for cancer predisposition studies. Moreover, we developed two program packages, enabling registration of patients, clinical data and samples at the participating hospitals as well as the central system of sample/data management at coordinating center. The approach used by us may serve as a model for dispersed biobanking from multiple satellite hospitals. Our biobanking resource ought to stimulate research into genetic mechanisms underlying the development of common cancers. It will allow all available “-omics” approaches on DNA-, RNA-, protein- and tissue levels to be applied. The collected samples can be made available to other research groups.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........7ae857a624ee6c48cb2b62fe440167f0